DDInter1259 DDInter596
Nalidixic acid is a synthetic 1,8-naphthyridine antimicrobial agent with a limited bacteriocidal spectrum. It is an inhibitor of the A subunit of bacterial DNA gyrase.
Doxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var. caesius along side with daunorubicin, another cytotoxic agent, in 1970.[A1575,A257709,A257614] Although they both have aglyconic and sugar moieties, doxorubicin's side chain terminates with a primary alcohol group compared to the methyl group of daunorubicin. Although its detailed molecular mechanisms have yet to be understood, doxorubicin is generally thought to exert its effect through DNA intercalation, which eventually leads to DNA damage and the generation of reactive oxygen species. Thanks to its efficacy and broad effect, doxorubicin was approved by the FDA in 1974 to treat a variety of cancer, including but not limited to breast, lung, gastric, ovarian, thyroid, non-Hodgkin’s and Hodgkin’s lymphoma, multiple myeloma, sarcoma, and pediatric cancers.[A1573,A257614,L45231] However, one of the major side effects of doxorubicin is cardiotoxicity, which excludes patients with poor heart function and requires treatment termination once the maximally tolerated cumulative dose is reached.
Nalidixic acid {u} (Compound) upregulates {v} (Gene) PAK1
PAK1 {u} (Gene) is upregulated by {v} (Compound) Doxorubicin
Nalidixic acid {u} (Compound) causes {v} (Side Effect) Anaphylactic shock
Anaphylactic shock {u} (Side Effect) is caused by {v} (Compound) Doxorubicin
Nalidixic acid {u} (Compound) upregulates {v} (Gene) PAK1
PAK1 {u} (Gene) is upregulated by {v} (Compound) Daunorubicin
Daunorubicin {u} (Compound) resembles {v} (Compound) Doxorubicin
Nalidixic acid {u} (Compound) causes {v} (Side Effect) Anaphylactic shock
Anaphylactic shock {u} (Side Effect) is caused by {v} (Compound) Daunorubicin
Daunorubicin {u} (Compound) resembles {v} (Compound) Doxorubicin
Nalidixic acid {u} (Compound) resembles {v} (Compound) Norfloxacin
Norfloxacin {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Doxorubicin
Nalidixic acid {u} (Compound) resembles {v} (Compound) Pefloxacin
Pefloxacin {u} (Compound) binds {v} (Gene) TOP2A
TOP2A {u} (Gene) is bound by {v} (Compound) and {u} (Gene) is downregulated by {v} (Compound) Doxorubicin
Nalidixic acid {u} (Compound) resembles {v} (Compound) Norfloxacin
Norfloxacin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Daunorubicin
Daunorubicin {u} (Compound) resembles {v} (Compound) Doxorubicin
Nalidixic acid {u} (Compound) resembles {v} (Compound) Norfloxacin
Norfloxacin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Idarubicin
Idarubicin {u} (Compound) resembles {v} (Compound) Doxorubicin
Nalidixic acid {u} (Compound) upregulates {v} (Gene) PAK1
PAK1 {u} (Gene) is associated with {v} (Disease) kidney cancer
kidney cancer {u} (Disease) is treated by {v} (Compound) Doxorubicin
Nalidixic acid {u} (Compound) upregulates {v} (Gene) HERC6
HERC6 {u} (Gene) is regulated by {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Doxorubicin
Nalidixic acid (Compound) upregulates PAK1 (Gene) and PAK1 (Gene) is upregulated by Doxorubicin (Compound)
Nalidixic acid (Compound) causes Anaphylactic shock (Side Effect) and Anaphylactic shock (Side Effect) is caused by Doxorubicin (Compound)
Nalidixic acid (Compound) upregulates PAK1 (Gene) and PAK1 (Gene) is upregulated by Daunorubicin (Compound) and Daunorubicin (Compound) resembles Doxorubicin (Compound)
Nalidixic acid (Compound) causes Anaphylactic shock (Side Effect) and Anaphylactic shock (Side Effect) is caused by Daunorubicin (Compound) and Daunorubicin (Compound) resembles Doxorubicin (Compound)
Nalidixic acid (Compound) resembles Norfloxacin (Compound) and Norfloxacin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Doxorubicin (Compound)
Nalidixic acid (Compound) resembles Pefloxacin (Compound) and Pefloxacin (Compound) binds TOP2A (Gene) and TOP2A (Gene) is bound by Doxorubicin (Compound) and TOP2A (Gene) is downregulated by Doxorubicin (Compound)
Nalidixic acid (Compound) resembles Norfloxacin (Compound) and Norfloxacin may cause a moderate interaction that could exacerbate diseases when taken with Daunorubicin and Daunorubicin (Compound) resembles Doxorubicin (Compound)
Nalidixic acid (Compound) resembles Norfloxacin (Compound) and Norfloxacin may cause a moderate interaction that could exacerbate diseases when taken with Idarubicin and Idarubicin (Compound) resembles Doxorubicin (Compound)
Nalidixic acid (Compound) upregulates PAK1 (Gene) and PAK1 (Gene) is associated with kidney cancer (Disease) and kidney cancer (Disease) is treated by Doxorubicin (Compound)
Nalidixic acid (Compound) upregulates HERC6 (Gene) and HERC6 (Gene) is regulated by ABCB1 (Gene) and ABCB1 (Gene) is bound by Doxorubicin (Compound)